Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Frances D. Schulz was appointed as Director at Senti Biosciences, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On December 2, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board unanimously appointed Frances D. Schulz to fill a newly created vacancy on the Board resulting from the resignation of Dr. Farokhzad, such appointment to be effective upon the initial closing of the Offering.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Omid Farokhzad resigned as Director at Senti Biosciences, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On November 25, 2024, Omid Farokhzad, M.D., a member of the Board and the Audit Committee of the Board, notified the Board of his resignation as a director of the Company and all committees thereof, effective November 25, 2024.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Senti Biosciences, Inc.: Filed Certificate of Designation with Delaware Secretary of State designating 21,200 shares of Series A Preferred Stock with stated value of $2,250.00 per share, setting forth rights, preferences and limitations (effective 2024-12-02).
- Change
- charter amendment
- Effective
- 2024-12-02
Exact text from the filing
on December 2, 2024, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 21,200 shares of its authorized and unissued preferred stock as Series A Preferred Stock, each with a stated value of $2,250.00 per share
View on SEC.gov